← Back to contracts

PRIMED-AI: Translating Models to Clinic (UG3/UH3 Clinical Trial Optional)

US · IL National Institutes of Health (NIH) grant unknown #RFA-RM-26-013

Summary

The National Institutes of Health (NIH) is issuing a Request for Applications (RFA) under the PRIMED-AI initiative to fund research translating artificial intelligence/machine learning models into clinical settings. The cooperative agreement mechanism is UG3/UH3, indicating a phased approach where UG3 represents a planning/milestone-driven phase transitioning to UH3 for implementation. Clinical trials are optional under this opportunity. The opportunity is currently in forecasted status with an open date of June 10, 2025.

What they want

Technical requirements
  • Research must focus on translating AI/ML models into clinical practice
  • Clinical trial component is optional but must be addressed in application design
  • Phased UG3 (planning/milestone) to UH3 (implementation) cooperative agreement structure required

How they evaluate

Submission: Grants.gov federal grants portal submission

Risks & flags

  • Opportunity is in 'forecasted' status — full requirements, eligibility, and evaluation criteria are not yet published, limiting early competitive preparation.
  • UG3/UH3 phased mechanism with milestone-gated transition may favor teams with pre-existing NIH cooperative agreement infrastructure and relationships.

Market context

inferred from NAICS
R&D in Physical, Engineering, Life Sciences (except Nanotech & Biotech)
NAICS 541715
US market size
$95B
Typical award
$100K – $50M+
Typical buyers
DoDNSFNIHNASADOE
Commonly required
DCAA-compliant accountingITARCMMC L2
PRIMED-AI: Translating Models to Clinic (U…
$unknown
Onboard ↗